Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04DYC
|
|||
Former ID |
DIB001112
|
|||
Drug Name |
PF-06463922
|
|||
Synonyms |
SCHEMBL15274056
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1/2 | [2], [3] | ||
Company |
Pfizer
|
|||
Structure |
Download2D MOL |
|||
Formula |
C21H19FN6O2
|
|||
Canonical SMILES |
CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
|
|||
InChI |
1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
|
|||
InChIKey |
IIXWYSCJSQVBQM-LLVKDONJSA-N
|
|||
CAS Number |
CAS 1454846-35-5
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ChEBI ID |
CHEBI:143117
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | ALK tyrosine kinase receptor (ALK) | Target Info | Inhibitor | [4] |
KEGG Pathway | Non-small cell lung cancer | |||
WikiPathways | Differentiation Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7476). | |||
REF 3 | ClinicalTrials.gov (NCT01970865) A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations. U.S. National Institutes of Health. | |||
REF 4 | PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.